Find trials
Consejos para buscar

Muscle Metabolism Characteristics Related to Diabetes-Related Conditions

Overview

Información sobre este estudio

Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM), whereas lower body obesity (LBO) is characterized by near-normal insulin sensitivity. It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking differs between different obesity phenotypes. Likewise, we do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. By measuring muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates we will provide the first integrated examination of the interaction between FFA and muscle insulin action from the whole body to the cellular/molecular level. By identifying which steps in the insulin signaling pathway are most affected, we will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance.
Hypothesis 1: Greater trafficking of plasma FFA into intramyocellular DG will impair proximal insulin signaling and reduce muscle glucose uptake.
Hypothesis 2: Greater trafficking of plasma FFA into intramyocellular ceramides will impair distal insulin signaling and reduce muscle glucose uptake.
Hypothesis 3: The uptake of plasma FFA destined to intramyocellular triglycerides is increased relative to FFA concentrations in UBO and T2DM compared with LBO.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Subjects 
    • sedentary, normal weight, premenopausal women and sedentary, age-matched normal weight men
    • healthy LBO (lower body obesity) premenopausal women and healthy, age-matched LBO men will be recruited as the “insulin sensitive” obese group
    • UBO (upper body obesity) premenopausal women and  age-matched UBO men will serve as the insulin resistant, non-diabetic group
    • UBO, T2DM premenopausal women and  age-matched UBO, T2DM men (same BMI) will comprise the most insulin resistant group
  • age range will be 18-55 years
  • In certain cases were premenopausal state is uncertain, serum FSH will be added on screening blood test for further clarification

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Michael Jensen, M.D.

Cerrado para la inscripción

Contact information:

Pamela Reich

(507) 255-6062

Reich.Pamela@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20307514

Mayo Clinic Footer